Author(s): Prabhat Jain, Geeta Parkhe

Email(s): scanresearchlab@gmail.com

DOI: 10.5958/0974-360X.2020.00971.3   

Address: Prabhat Jain*, Geeta Parkhe
Scan Research Laboratories, Sector A H No. 109, J K Road, Indrapuri, Bhopal, MP 462023.
*Corresponding Author

Published In:   Volume - 13,      Issue - 11,     Year - 2020


ABSTRACT:
The main purpose of any drug delivery system is to supply a therapeutic amount of drug to a target site in a body, so that the necessary drug concentration can be achieved quickly and then maintained. Targeted drug delivery implies discerning and effective localization of drug into the target at therapeutic concentrations with limited admittance to non-target sites. A targeted drug delivery system is favoured in drugs having low solubility, instability, short half-life, large volume of distribution, reduced absorption, low specificity and low therapeutic index. Targeted drug delivery may afford maximum therapeutic activity by preventing degradation or inactivation of drug during transfer to the target site. Occurrence of inflammatory bowel diseases has enlarged at an alarming rate. The treatment and extent of therapy is determined by the sternness of the circumstances. Conventional therapies are insufficient and are connected with several systemic side effects because of lack to localization of active moiety at the irritated site. Colon targeted drug delivery is an vigorous area of research for local diseases affecting the colon, as it improves the competence of therapeutics and enables restricted treatment, which reduces universal toxicity. Targeted delivery of therapeutics to the colon is mainly advantageous for the treatment of inflammatory bowel disease (IBD) is a chronic autoimmune disease, which includes ulcerative colitis and Crohn's disease is considered by chronic relapsing inflammation of the gastrointestinal tract. Advances in oral drug delivery plan have considerably enhanced the bioavailability of drugs to the colon; though in order for a drug to have therapeutic efficiency during disease, considerations have to be made for the altered physiology of the gastrointestinal (GI) tract that is connected with GI inflammation. The current review discusses the novel and the latest planned approaches of colonic drug targeting exclusively concentrating the drug at inflamed site and thereby achieving successful treatment routine.


Cite this article:
Prabhat Jain, Geeta Parkhe. Alternative Colon Targeted Drug Delivery Approaches for the Treatment of Inflammatory Bowel Disease. Research J. Pharm. and Tech. 2020; 13(11):5562-5568. doi: 10.5958/0974-360X.2020.00971.3


REFERENCES:
1.    Takedatsu H, Mitsuyama K, Torimura T. Nanomedicine and drug delivery strategies for treatment of inflammatory bowel disease. World J Gastroenterol 2015; 21: 11343-11352.
2.    Kappelman MD, Moore KR, Allen JK, Cook SF. Recent Trends in the Prevalence of CD and UC in a Commercially Insured US Population. Dig Dis Sci 2013; 58: 519-525.
3.    Goh J, O'Morain CA. Review article: nutrition and adult inflammatory bowel disease. Aliment Pharmacol Ther 2003; 17: 307-320.
4.    Blumberg RS, Strober W. Prospects for research in inflammatory bowel disease. JAMA 2001; 285: 643-647.
5.    Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-429.
6.    Hua S, Marks E, Schneider JJ, Keely S. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: Selective targeting to diseased versus healthy tissue. Nanomedicine 2015; 11: 1117-1132.
7.    Triantafillidis JK, Merikas E, Georgopoulos F. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther 2011; 5: 185-210.
8.    Devlin SM, Panaccione R. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. Med Clin North Am 2010; 94: 1-18.
9.    Amidon S, Brown Jack E, Dave Vivek S. Colon targeted oral drug delivery system design trends and approach AAPS Pharma SciTech 2015; 16(4); 731-741.
10.    Prasanth VV, Jayabrakash R, Sam M. Colon specific drug delivery system a review on various pharmaceutical approaches. J Applied Pharma Sci 2012; 2(1); 163-69.
11.    Rajpurohit H, Sharma P, Sharma, Bhandari A. Polymers for colon targeted drug delivery system. Indian J Pharm Sci 2010; 72(6); 689-969.
12.    Tortora GT, Grabowski SR. Gastric system. Principles of anatomy and physiology. 8th ed. Philadelphia: Wiley & Sons. pp 793.
13.    Dewan N, Ahmed AB, Dasgupta D.  Review on colon targeted drug delivery for inflammatory bowel disease. The Pharma Innovation Journal 2018; 7(1): 98-103.
14.    Jain NK. Colon targeted drug delivery. Advances in controlled and novel drug delivery, CBS publishers, Delhi, 2001.
15.     Lee HL, Mukherjee SK. Drug delivery-oral colon-specific. Encyclopedia of pharmaceutical technology, 2002, 871-885.James swarbrick, Informa Health Care, 2006, NY.
16.    Liu L, Fishman ML, Kost J, Hicks KB. Pectin based systems for colon-specific drug delivery via oral route. Biomaterials. 2003; 24:3333-3343.
17.    Demiroz FT, Acarturk F, Takka S, Boyunaga KO. Evaluation of alginate based mesalazine tablets for intestinal drug delivery. Eur J Pharma Biopharm 2007; 67: 491-497.
18.    Newton AMJ, Kumar N. IBD–Impact of colonic pH, onset of action and other factors in modern therapeutic approach inter discip. J Microinflammation 2014; 1(2): 1-7.
19.    Wallace JL. Nitric oxide-releasing mesalamine: potential utility for treatment of inflammatory bowel disease. Dig Liver Dis 2003; 35 Suppl 2: S35-40.
20.     Green JR, Mansfield JC, Gibson JA, Kerr GD, Thornton PC. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment Pharmacol Ther 2002; 16: 61-68.
21.    Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347:417-429.
22.    Sands BE. Medical therapy of steroid-resistant Crohn’s disease. Can J Gastroenterol 2000;14:33C–37
23.    Jani N, Regueiro MD. Medical therapy for ulcerative colitis. Gastroenterol Clin North Am 2002; 31:147-166.
24.    Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, et al. Anti-IL-12Crohn’sDisease StudyGroup. Antiinterleukin-12 antibody for active Crohn’s disease. N Engl J Med 2004; 351:2069-2079.
25.    Ogata H, Hibi T. Cytokine and anti-cytokine therapies for inflammatory bowel disease. Curr Pharm Des 2003; 9:1107-1113.
26.    Steidler L. In situ delivery of cytokines by genetically engineered Lactococcus lactis. Antonie Van Leeuwenhoek 2002; 82:323-331.
27.    Barbara G, Xing Z, Hogaboam CM, Gauldie J, Collins SM. Interleukin 10 gene transfer prevents experimental colitis in rats. Gut 2000; 46:344-349.
28.    Yang L, Chu JS, Fix JA. Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. Int J Pharm 2002; 235: 1-15.
29.    Meissner Y, Lamprecht A. Alternative drug delivery approaches for the therapy of inflammatory bowel disease. J Pharm Sci 2008; 97: 2878-2891.
30.    Vadnerkar G, Dhaneshwar S. Macromolecular prodrug of 4-aminosalicylic acid for targeted delivery to inflamed colon. Curr Drug Discov Technol 2013; 10: 16-24.
31.    Friend DR, Chang GW. A colon-specific drug-delivery system based on drug glycosides and the glycosidases of colonic bacteria. J Med Chem 1984; 27: 261-266.
32.    Sinha VR, Kumria R. Polysaccharides in colon-specific drug delivery. Int J Pharm 2001; 224: 19-38.
33.    Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci 2003; 6: 33-66.
34.    McConnell EL, Fadda HM, Basit AW. Gut instincts: Explorations in intestinal physiology and drug delivery. Int J Pharm 2008; 364: 213-226.
35.    Lautenschläger C, Schmidt C, Fischer D, Stallmach A. Drug delivery strategies in the therapy of inflammatory bowel disease. Adv Drug Deliv Rev 2014; 71: 58-76.
36.     Fukui E, Miyamura N, Uemura K, Kobayashi M. Preparation of enteric coated timed-release press-coated tablets and evaluation of their function by in vitro and in vivo tests for colon targeting. Int J Pharm 2000; 204: 7-15.
37.    Wakerly Z, Fell JT, Attwood D, Parkins D. Studies on drug release from pectin/ethylcellulose film-coated tablets: a potential colonic delivery system. Int J Pharm 1997; 153:219-224.
38.    Rubinstein A, Radai R, Ezra M, Pathak S, Rokem JS. In vitro evaluation of calcium pectinate: a potential colon-specific drug delivery carrier. Pharm Res 1993; 10: 258-263.
39.    Singh N, Khanna R. Colon targeted drug delivery systems -A Potential Approach. The Pharma Innovation 2012; 1: 38-48.
40.    Qiu Y, Park K. Environment-sensitive hydrogels for drug delivery. Adv Drug Deliv Rev 2001; 53: 321-339.
41.    Talaei F, Atyabi F, Azhdarzadeh M, Dinarvand R, Saadatzadeh A. Overcoming therapeutic obstacles in inflammatory bowel diseases: a comprehensive review on novel drug delivery strategies. Eur J Pharm Sci 2013; 49: 712-722.
42.    Nidhi, Rashid M, Kaur V, Hallan SS, Sharma S, Mishra N. Microparticles as controlled drug delivery carrier for the treatment of UC: A brief review. Saudi Pharma J 2014.
43.    Atyabi F, Vahabzadeh R, Dinarvand R. Preparation of ethylcellulose coated gelatin microspheres as a multiparticulate colonic delivery system for 5-aminosalicilic acid. Iran J Pharm Res 2010; 81-26.
44.    D’Souza AA, Devarajan PV. Bioenhanced oral curcumin nanoparticles: Role of carbohydrates. Carbohydrate polymers 2016; 136: 1251-1258.
45.    Guslandi M. A natural approach to treatment of inflammatory bowel disease. Br J Clin Pharmacol 2008; 65: 468-469.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags